 Home > Chemicals Industry > China Chemical > The 2021 semi-annual performance forecast arranges the overall stable development of the domestic instrument industry

The 2021 semi-annual performance forecast arranges the overall stable development of the domestic instrument industry

 Last Update: 2021-07-31
 Source: Internet
 Author: User

Tags

chemical composition cocaine

precision attachment

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

[ Star Enterprise of Chemical Machinery Equipment Network ] 2021 has passed halfway.
As the impact of the epidemic gradually diminishes, the domestic market environment has basically returned to normal
.
After getting rid of the impact of the epidemic, how has the development of the domestic instrument industry changed?

Chemical machinery and equipment network star enterprise chemical machinery and equipment

Before the official semi-annual reports of major domestic instrument companies were released, Chemical Instrument Network compiled the semi-annual performance forecasts of some companies, from which we can roughly learn the development status of China's instrument industry in the first half of 2021
.

Su test test: performance is expected to rise in the same direction

On July 14, Suzhou Sutest Test Group Co.
, Ltd.
released the 2021 semi-annual results forecast
.
According to the content of the report, during the reporting period (January 1, 2021-June 30, 2021), the net profit attributable to shareholders of the listed company in the Su test trial is expected to be RMB 73,780,100 to RMB 83,617,400, an increase of 50% over the same period of the previous year.
%-70%
.

Explanation of reasons for performance changes:

1.
During the reporting period, the overall growth of test equipment and test service segments was significant, especially the rapid growth of environmental reliability test service business.
The test service business accounted for a further increase in the proportion of main business income.
At the same time, the profitability of the integrated circuit verification analysis service business was significantly improved
.

　　2.
During the reporting period, it is estimated that the impact of non-recurring gains and losses on net profit is RMB 7,123,800, and the impact of non-recurring gains and losses on net profit of the same period last year is RMB 8,126,000
.

　　Xuedilong: expected performance to rise in the same direction

　　On July 15, Beijing Xuedilong Technology Co.
, Ltd.
issued an announcement on the revision of the 2021 semi-annual results forecast
.
According to the content of the announcement, during the reporting period (January 1, 2021 to June 30, 2021), the net profit attributable to shareholders of the listed company was RMB 105 million to RMB 125 million, an increase of 1030.
80% over the same period of the previous year.
-1246.
18%
.
Basic earnings per share are 0.
17 yuan/share-0.
21 yuan/share
.

　　Explanation of reasons for performance changes:

　　Affected by the epidemic in the same period last year, the company's operating income and net profit have declined; in 2021, the company's production and operation will return to normal
.

　　Explanation of reasons for performance revision:

　　During the reporting period, the company's business development and project acceptance were relatively smooth, and business income increased compared with previous estimates, so profits increased
.

　　Libang Instruments: expected performance to decline in the same direction

　　On July 14, Shenzhen Libang Precision Instrument Co.
, Ltd.
released the 2021 semi-annual results forecast
.
According to the content of the report, during the reporting period (January 1, 2021-June 30, 2021), the operating income of Libang Instruments is expected to be RMB 8,687,733,900-9,198,359,900, a decrease of 28%-32% over the same period of the previous year
.
The net profit attributable to shareholders of listed companies was 174,934,700 yuan-19,874,600 yuan, a decrease of 58% -63% over the same period of the previous year
.
After deducting non-recurring gains and losses, the net profit was 158,345,700 yuan and 180,338,100 yuan, a decrease of 59%-64% over the same period of the previous year
.

　　Explanation of reasons for performance changes:

　　1.
Since 2021, with the gradual alleviation of the domestic epidemic, the operating environment of the domestic market has greatly improved compared with the same period last year.
Related markets and sales activities have been carried out normally, and the sales of each product line have achieved steady growth; the international market has not been directly related to the epidemic.
In addition to the related monitoring product lines, the sales of other product lines have also achieved steady growth
.
The main reason for the decline in the monitoring product line is that the second quarter of 2020 is the peak of the outbreak of the epidemic in overseas markets, and overseas countries have a huge demand for monitoring products
.
During the reporting period, with the gradual stabilization of the epidemic situation in overseas countries, the demand for monitoring products dropped significantly year-on-year
.
Based on the above reasons, the company's sales revenue and profit for the current period decreased by a certain percentage compared with the same period last year
.

　　2.
The impact of the company's non-recurring gains and losses on net profit during the reporting period is estimated to be about 18 million yuan, mainly due to government subsidies
.
The current government subsidies decreased by about 21 million yuan compared with the same period last year
.

　　Radio and Television Measurement: Estimated performance loss

　　On July 13, Guangzhou Guangdian Metrology and Inspection Co.
, Ltd.
released the 2021 semi-annual performance forecast
.
According to the content of the report, during the reporting period (January 1, 2021-June 30, 2021), the operating income of the Radio and Television Measurement is expected to be 81.
5 billion-83.
5 million yuan, an increase of 42.
08%-45.
56% over the same period of the previous year
.
The net profit loss attributable to shareholders of the listed company was 2.
5 million to 1.
5 million yuan, and the basic earnings per share loss was 0.
05 yuan/share-0.
03 yuan/share.
Compared with the same period last year, the degree of loss of both has been greatly reduced
.

　　Explanation of reasons for performance changes:

　　1.
During the reporting period, the company continued to strengthen market expansion, improved laboratory layout, and strengthened operational control.
Orders increased significantly, operating income achieved rapid year-on-year growth, and net profit attributable to shareholders of listed companies achieved a significant year-on-year reduction in losses; but the Guangdong region The epidemic from May to June had a certain impact on the business development of the company's headquarters, resulting in delayed completion of some orders, and failure to turn losses during the reporting period
.

　　2.
During the reporting period, the company continued to strengthen cost control and promote refined management; however, the company's labor costs have grown rapidly, and the company's laboratory technology has continued to invest in recent years, and fixed costs such as depreciation and amortization have increased rapidly during the reporting period
.

　　3.
During the reporting period, the impact of non-recurring gains and losses on the company's net profit is estimated to be RMB 1.
2 billion; the impact of non-recurring gains and losses on the company's net profit in the same period last year is RMB 14.
8206 million
.

　　Lihe Technology: Expected performance to be basically flat

　　On July 13, Lihe Technology (Hunan) Co.
, Ltd.
released the 2021 semi-annual results forecast
.
According to the content of the report, during the reporting period (January 1, 2021-June 30, 2021), the net profit of Lihe Technology attributable to shareholders of listed companies was RMB 10,078,300 to RMB 13,540,100, a change compared with the same period of the previous year.
The range is: -15.
00% to 15.
00%
.

　　Explanation of reasons for performance changes:

　　1.
The company's production and operation are normal, and its performance is expected to be basically the same as that of the same period last year
.

　　2.
During the reporting period, it is estimated that the impact of non-recurring gains and losses on net profit is approximately 16.
64 million yuan.
The specific data is subject to the data disclosed in the 2021 semi-annual report
.

　　Tailin Bio: expected performance to rise in the same direction

　　On July 13, Zhejiang Tailin Biotechnology Co.
, Ltd.
released the 2021 semi-annual results forecast
.
According to the content of the report, during the reporting period (January 1, 2021-June 30, 2021), the net profit of Tailin Biotech attributable to shareholders of listed companies was 25.
61 million yuan-31.
1 million yuan, an increase compared with the same period of the previous year.
40%-70%
.
The net profit after deducting non-recurring gains and losses was 24.
31 million yuan to 29.
8 million yuan, an increase of 56%-92% over the same period of the previous year
.
Basic earnings per share are 0.
49 yuan/share-0.
60 yuan/share
.

　　Explanation of reasons for performance changes:

　　1.
During the reporting period, the company's microbiological testing series, isolation and sterilization series, organic matter analysis series and other products have achieved growth in sales, so that the semi-annual overall sales revenue maintained growth
.

　　2.
During the reporting period, the estimated amount of non-recurring gains and losses is approximately 1.
3 million yuan
.

　　Huada Gene: expected performance to decline in the same direction

　　On July 14, Shenzhen Huada Gene Co.
, Ltd.
released the 2021 semi-annual results forecast
.
According to the content of the report, during the reporting period (January 1, 2021-June 30, 2021), BGI Gene's operating income was approximately 3.
5 billion-3.
75 million yuan, a decrease of approximately 8.
71%-14.
80% from the same period last year
.
The net profit attributable to shareholders of listed companies was RMB 1.
0 billion to RMB 1.
2 billion, a decrease of 27.
34%-39.
45% compared with the same period of the previous year
.
After deducting non-recurring gains and losses, the net profit was 965 million yuan to 1.
195 million yuan, a decrease of 25.
52%-39.
86% from the same period last year
.
Basic earnings per share are 2.
4488 yuan/share-2.
9385 yuan/share
.

　　Explanation of reasons for performance changes:

　　1.
During the reporting period, due to the global decline in the unit price of COVID-19 nucleic acid detection reagents and services, the company's revenue from COVID-19-related comprehensive solutions for precision medical testing decreased compared with the same period in 2020
.

　　2.
During the reporting period, the company continued to increase R&D investment and forward-looking product layout, and accelerated the increase in global market share.
Excluding changes in the new crown business, the company's regular business segments achieved steady and organic growth compared with the same period last year
.
Among them, tumor prevention and control, infection prevention and control-related business sample size and revenue have achieved substantial growth over the same period last year
.

　　3.
During the reporting period, the company's sales expenses increased significantly over the same period of the previous year
.
R&D expenses increased steadily compared to the same period last year
.

　　4.
During the reporting period, the impact of the company's non-recurring gains and losses on the company's net profit amounted to approximately 5 million to 35 million yuan
.

　　Original title: 2021 semi-annual performance forecast finishing domestic instrument industry overall stable development

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.